Compass Therapeutics Inc. (NASDAQ: CMPX) announced that its experimental drug tovecimig met a key secondary endpoint in a Phase 2/3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE